Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Sun Pharmaceutical Industries Ltd. closed 14.48% below its 52-week high of 1,960.20 rupees, which the company reached on ...

The New Jersey Economic Development Authority board March 12 approved $5.24 million in tax credits under the Emerge Program ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and ...

Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

The NJEDA Board approved tax credits under the Emerge Program to support Sun Pharmaceutical Industries Inc.’s plan to open a new ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said ...

Sun Pharmaceutical Industries Ltd. closed 14.10% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.